NATICK, Mass.--(BUSINESS WIRE)-- AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today that it will present an abstract in a poster session at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10, 2024, in San Diego, California. Presented findings will highlight research applying the affinity-tuned, trackable, ICAM-1 targeting CAR T cell therapy AIC100 to additional solid tumor types where there is significant unmet medical need.
Details of the poster presentation are as follows:
Poster Title: AIC100CAR-T cells targeting ICAM-1 are efficacious against solid tumors in xenograft mouse models of Non-Small Cell Lung Cancer (NSCLC) and Cervical Cancer (CC).
Date and Time: Tuesday Apr 9, 2024, 9:00 AM - 12:30 PM
Presenting Author: Alyssa Birt, AffyImmune Therapeutics
Session Category: Immunology
Session Title: Adoptive Cell Therapies 3: CAR-T Cells
Location: Poster Section 2, Poster Board Number: 16
Published Abstract Number: 4007
About AffyImmune TherapeuticsAffyImmune is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR-T cell therapies to transform the lives of patients with cancer. The Company’s proprietary technology utilizing ICAM1/LFA-1 interaction can potentially address all critical CAR-T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion, while also allowing in vivo tracking of the CAR-T cells. Its lead candidate, AIC100, is a ICAM1-directed CAR-T therapy being developed for patients with advanced thyroid cancer. AffyImmune is developing a focused pipeline of therapeutics targeting ICAM-1 in oncologic indications with high unmet medical need. AffyImmune is based in Natick, MA. For more information, visit .
View source version on businesswire.com:
Contacts
Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
Source: AffyImmune Therapeutics, Inc.
View this news release online at:
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.